Back to Journals » OncoTargets and Therapy » Volume 9

Biomarkers in pancreatic adenocarcinoma: current perspectives

Authors Swords DS, Firpo MA, Scaife CL, Mulvihill SJ

Received 1 September 2016

Accepted for publication 20 September 2016

Published 9 December 2016 Volume 2016:9 Pages 7459—7467

DOI https://doi.org/10.2147/OTT.S100510

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ashok Kumar Pandurangan

Peer reviewer comments 2

Editor who approved publication: Dr Yao Dai


Douglas S Swords, Matthew A Firpo, Courtney L Scaife, Sean J Mulvihill

Department of Surgery, University of Utah Health Sciences, Salt Lake City, UT, USA

Abstract: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival rate of 7.7%. Most patients are diagnosed at an advanced stage not amenable to potentially curative resection. A substantial portion of this review is dedicated to reviewing the current literature on carbohydrate antigen (CA 19-9), which is currently the only guideline-recommended biomarker for PDAC. It provides valuable prognostic information, can predict resectability, and is useful in decision making about neoadjuvant therapy. We also discuss carcinoembryonic antigen (CEA), CA 125, serum biomarker panels, circulating tumor cells, and cell-free nucleic acids. Although many biomarkers have now been studied in relation to PDAC, significant work still needs to be done to validate their usefulness in the early detection of PDAC and management of patients with PDAC.

Keywords: pancreatic cancer, biomarkers, screening, CA 19-9, CEA

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]